It is a multicentric trial conducted at the above centres and the results were summarized as follows :

  PID is a common condition with considerable degree of physical and emotional morbidity. 50 patients were treated with 2ml IM Placentrex x 21 days and 50 on conventional anti-inflammatory drug therapy. Patients were followed up for a period   of four months after completion of protocol therapy.

  The number of patients reporting improvement in presenting symptoms of abdominal pain, dysmenorrhoea etc. was   statistically significant in the PLACENTREX group. Abdominal tenderness disappeared in statistically significant number of   patients in the PLACENTREX group.

  There were statistically more number of patients in the Placentrex group in whom excellent to good response was seen at   the end of four months after completion of protocol therapy.

  It can be observed that IM Placentrex is useful addition to the therapeutic armamentarium in the management of patients   with pelvic inflammatory disease. Its therapeutic effect persists for a period of at least four months after completion of 21   days therapy as per the present protocol. IM Placentrex is well accepted and tolerated by the patients without any side   effects.

Abdominal Pain: Control (n-= 50) Initial Final Sig. Absent 0 19 N.S. Same   17 N.S. Increased   6   Reduced   8   Placentrex (n = 50)       Absent   30 P<0.01 Same   6   Increased   3   Reduced   11 P<0.05 Significance     P<0.05 for Px

Abdominal Tenderness: Control (n-= 50) Initial Final Sig. Absent   20 N.S. Same   10 N.S. Increased   8   Reduced   12   Placentrex (n = 50)       Absent   39 P<0.01 Same   6   Increased   0   Reduced   5 P<0.05 Significance     P<0.05 for Px